Cargando…

Utility of Pretreatment Bilirubin Level and UGT1A1 Polymorphisms in Multivariate Predictive Models of Neutropenia Associated with Irinotecan Treatment in Previously Untreated Patients with Colorectal Cancer

PURPOSE: Statistical models for predicting hematologic toxicity were evaluated based on UGT1A1 polymorphisms and baseline serum bilirubin. METHODS: Blood DNA samples were collected from 113 patients with untreated metastatic colorectal cancer receiving irinotecan (FOLFIRI, n = 36; mIFL, n = 41; Cape...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parodi, Luis, Pickering, Eve, Cisar, Laura A, Lee, Doug, Soufi-Mahjoubi, Raoudha
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2008
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2710994/ https://www.ncbi.nlm.nih.gov/pubmed/19639031 http://dx.doi.org/10.1111/j.1753-5174.2008.00014.x

Ejemplares similares

UGT1A1 polymorphisms in cancer: impact on irinotecan treatment
por: Takano, Masashi, et al.
Publicado: (2017)

UGT1A1-related Bilirubin Encephalopathy/Kernicterus in Adults
por: Bai, Jie, et al.
Publicado: (2021)

Association between the low-dose irinotecan regimen-induced occurrence of grade 4 neutropenia and genetic variants of UGT1A1 in patients with gynecological cancers
por: MORIYA, HIROYUKI, et al.
Publicado: (2014)

Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer
por: Kinoshita, A, et al.
Publicado: (2006)

Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis
por: Fukuda, Akito, et al.
Publicado: (2022)

Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy
por: Liu, Xing-Han, et al.
Publicado: (2017)

The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan
por: Su, Y.-Y., et al.
Publicado: (2022)

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1
por: de With, Mirjam, et al.
Publicado: (2023)

Bilirubin Level is Associated with Left Ventricular Hypertrophy Independent of Blood Pressure in Previously Untreated Hypertensive Patients
por: Ayaz, Teslime, et al.
Publicado: (2014)

Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan‐related toxicities in patients with lung cancer
por: Fukuda, Minoru, et al.
Publicado: (2017)

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
por: Marcuello, E, et al.
Publicado: (2004)

Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer
por: Fujii, Hironori, et al.
Publicado: (2018)

UGT1A1 is a major locus influencing bilirubin levels in African Americans
por: Chen, Guanjie, et al.
Publicado: (2012)

Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer
por: Hong, Y S, et al.
Publicado: (2006)

Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI
por: Lee, Lawrence Soon-U, et al.
Publicado: (2016)

Dosage Adjustment of Irinotecan in Patients with UGT1A1 Polymorphisms: A Review of Current Literature
por: Argevani, Lia, et al.
Publicado: (2020)

Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis
por: Xu, Fei, et al.
Publicado: (2018)

UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan
por: Kimura, Kei, et al.
Publicado: (2018)

Impact of UGT1A1 genotype on the efficacy and safety of irinotecan‐based chemotherapy in metastatic colorectal cancer
por: Iwasa, Satoru, et al.
Publicado: (2021)

UGT1A1 sequence variants and bilirubin levels in early postnatal life: a quantitative approach
por: Hanchard, Neil A, et al.
Publicado: (2011)

Neobavaisoflavone Induces Bilirubin Metabolizing Enzyme UGT1A1 via PPARα and PPARγ
por: Zhu, Ya-Di, et al.
Publicado: (2021)

Serum Bilirubin Levels and Promoter Variations in HMOX1 and UGT1A1 Genes in Patients with Fabry Disease
por: Jirásková, Alena, et al.
Publicado: (2017)

A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes
por: TSUNEDOMI, RYOUICHI, et al.
Publicado: (2014)

Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer
por: Li, Minmin, et al.
Publicado: (2014)

Molecular Genetics External Quality Assessment Pilot Scheme for Irinotecan-Related UGT1A1 Genotyping in China
por: Yi, Lang, et al.
Publicado: (2016)

Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy
por: Bai, Yu, et al.
Publicado: (2017)

Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray
por: Tsunedomi, Ryouichi, et al.
Publicado: (2017)

Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1 * 28 or * 6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A)
por: Fukuda, Minoru, et al.
Publicado: (2016)

UGT1A1 promoter polymorphism associated with serum bilirubin level in Saudi patients with sickle cell disease
por: Hamad, Zainab, et al.
Publicado: (2013)

UGT1A1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab
por: Lin, Nan, et al.
Publicado: (2022)

Influence of UGT1A1 Genetic Variants on Free Bilirubin Levels in Japanese Newborns: A Preliminary Study
por: Hanafusa, Hiroaki, et al.
Publicado: (2022)

Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration
por: Sy, S. Kenneth, et al.
Publicado: (2016)

Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer
por: Jo, J-C, et al.
Publicado: (2012)

Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
por: Liu, X, et al.
Publicado: (2014)

The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer
por: Xiao, Xiao-guang, et al.
Publicado: (2015)

Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism
por: Jannin, Arnaud, et al.
Publicado: (2017)

Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1(*)6 or UGT1A1(*)28
por: Tian, Chuan, et al.
Publicado: (2018)

Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan‐induced toxicity in Asian cancer patients: Meta‐analysis
por: Atasilp, Chalirmporn, et al.
Publicado: (2022)

Impairment of enzymatic antioxidant defenses is associated with bilirubin-induced neuronal cell death in the cerebellum of Ugt1 KO mice
por: Bortolussi, G, et al.
Publicado: (2015)

Serum Bilirubin Concentration in Healthy Adult North-Europeans Is Strictly Controlled by the UGT1A1 TA-Repeat Variants
por: Kringen, Marianne K., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_itlouilrkk0u50vcckespnfj44